IL10 and type 1 diabetes mellitus: In a 2009 Phase I study in individuals with type 1 diabetes, those who were given low doses of proinsulin peptide showed an increase in peptide-specific IL-10 responses when compared with individuals given placebo, demonstrating proof of concept [91].